We report here the optimization of an HldE kinase inhibitor to low nanomolar potency, which resulted in the identification of the first reported compounds active on selected E. coli strains. One of the most interesting candidates, compound 86, was shown to inhibit specifically bacterial I,PS heptosylation on efflux pump deleted E. coli strains. This compound did not interfere with E. coli bacterial growth (MIC > 32 mu g/mL) but sensitized this pathogen to hydrophobic antibiotics like macrolides normally inactive on Gram-negative bacteria. In addition, 86 could sensitize E. coli to serum complement killing. These results demonstrate that HldE kinase is a suitable target for drug discovery. They also pave the way toward novel possibilities of treating or preventing bloodstream infections caused by pathogenic Gram negative bacteria by inhibiting specific virulence factors.
ANTI-INFECTIVE COMPOUNDS
申请人:Institut Pasteur Korea
公开号:EP3027615B1
公开(公告)日:2021-07-21
Anti-Infective Compounds
申请人:INSTITUT PASTEUR KOREA
公开号:US20160185774A1
公开(公告)日:2016-06-30
The present invention relates to small molecule compounds and their use in the treatment of bacterial infections, in particular Tuberculosis.
[EN] NEW 1,2,4-TRIAZINE DERIVATIVES AND BIOLOGICAL APPLICATIONS THEREOF<br/>[FR] NOUVEAUX DÉRIVÉS DE 1,2,4-TRIAZINE ET LEURS APPLICATIONS BIOLOGIQUES
申请人:MUTABILIS SA
公开号:WO2010001220A1
公开(公告)日:2010-01-07
The invention relates to new 1,2,4-triazine derivatives of formula (I): wherein A, B, R2 and Y are defined in the application, their preparation and intermediates, their use as drugs and pharmaceutical compositions and associations containing them. The compounds of formula (I) are capable of inhibiting bacterial heptose synthesis.